Prices and market caps: Cboe delayed data, at least 15 minutes delayed. Not real-time. Fundamentals from company filings.
Prices and market caps: Cboe delayed data, at least 15 minutes delayed. Not real-time. Fundamentals from company filings.
Krystal Biotech, Inc.
High uncertainty: The valuation methods show significant disagreement (>100% spread). Treat the range as a rough guide rather than a precise estimate.
Bear Case (25th pct.)
-73.8% vs price
Base Case (Median)
-63.0% vs price
Bull Case (75th pct.)
-42.6% vs price
◇ = Current price | | Bear | Base | Bull
| Method | Est. Value | vs Price | Weight |
|---|---|---|---|
| DCF (Discounted Cash Flow) | $119.20 | -63.0% | High (40%) |
| PE Comparable | $178.96 | -44.5% | Medium (25%) |
| Growth Trajectory DCF | $541.86 | 68.1% | Medium (20%) |
| Graham Number | $86.06 | -73.3% | Medium (40%) |
| EV/EBITDA | $82.59 | -74.4% | Medium (20%) |
| EV/FCF | $191.09 | -40.7% | Medium (20%) |
| Earnings Power Value | $32.35 | -90.0% | Medium (50%) |
Based on 7 out of 7 methods, KRYS appears overvalued at the current price of $322.28. The base case fair value of $119.20 implies 63.0% downside.
Bear/base/bull cases represent the 25th, 50th, and 75th percentile of available method estimates. This is not financial advice. Valuation is inherently uncertain.